Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38654078 | 0.89 | GAA (0.39) | HPGDMAPTTSHRGAAL3MBTL1 | |
| SCHEMBL30229980 | 0.77 | KMT2A (0.40) | TSHRL3MBTL1PKMMEN1KMT2A | |
| SCHEMBL30688759 | 0.76 | TSHR (0.36) | SIGMAR1POLBHPGDTSHRGAA | |
| SCHEMBL16351364 | 0.76 | ALDH1A1 (0.43) | HPGDMAPTGAAALDH1A1MEN1 | |
| SCHEMBL31122973 | 0.75 | CTSK (0.35) | HPGDMAPTTSHRGAAL3MBTL1 | |
| SCHEMBL28606626 | 0.74 | KDM4E (0.36) | HPGDMAPTTSHRGAAALDH1A1 | |
| SCHEMBL28410516 | 0.73 | GAA (0.42) | MAPTTSHRGAAL3MBTL1ALDH1A1 | |
| SCHEMBL554235 | 0.73 | SIGMAR1 (0.49) | SIGMAR1MAPTALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5496481 | 0.72 | MEN1 (0.64) | SIGMAR1POLBL3MBTL1SLC29A1MEN1 | |
| Hydrochloric Acid SCHEMBL31510126 | 0.72 | MEN1 (0.64) | SIGMAR1POLBL3MBTL1SLC29A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | SIGMAR1 4812/4885POLB 1699/4885HPGD 1741/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | SIGMAR1 4812/4885POLB 1699/4885HPGD 1741/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SIGMAR1 4812/4885POLB 1699/4885HPGD 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.